Marker Therapeutics (MRKR) Retained Earnings (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Retained Earnings of -$462.4 million for Q1 2026, down 2.41% year-over-year from -$473.8 million in Q1 2025, and down 197.14% quarter-over-quarter from $476.0 million in Q4 2025.
Marker Therapeutics (MRKR) Retained Earnings (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Retained Earnings for 17 consecutive years, with -$462.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 2.41% year-over-year to -$462.4 million; the TTM figure through Mar 2026 stood at -$462.4 million (down 2.41% YoY), while the FY2025 annual figure was $476.0 million, up 2.23% from the prior year.
- Retained Earnings retreated to -$462.4 million in Q1 2026 per MRKR's latest filing, from $476.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $476.0 million in Q4 2025 and bottomed at -$462.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$19.1 million across 5 years, with a median of -$417.3 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 221.54% — and 2024, when it tumbled 198.44%.
- Marker Therapeutics' Retained Earnings stood at $447.6 million in 2022, then sank by 197.46% to -$436.3 million in 2023, then soared by 206.71% to $465.6 million in 2024, then increased by 2.23% to $476.0 million in 2025, then tumbled by 197.14% to -$462.4 million in 2026.
- Business Quant data shows MRKR's Retained Earnings at -$462.4 million in Q1 2026, $476.0 million in Q4 2025, and -$457.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 476.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -462.36 Mn |
| Dec 31, 2025 | 475.96 Mn |
| Sep 30, 2025 | -457.48 Mn |
| Jun 30, 2025 | 465.96 Mn |
| Mar 31, 2025 | -451.46 Mn |
| Dec 31, 2024 | 465.56 Mn |
| Sep 30, 2024 | -443.18 Mn |
| Jun 30, 2024 | -440.87 Mn |
| Mar 31, 2024 | -438.68 Mn |
| Dec 31, 2023 | -436.29 Mn |
| Sep 30, 2023 | 450.18 Mn |
| Jun 30, 2023 | 449.53 Mn |
| Mar 31, 2023 | 448.92 Mn |
| Dec 31, 2022 | 447.64 Mn |
| Sep 30, 2022 | -424.19 Mn |
| Jun 30, 2022 | -417.27 Mn |
| Mar 31, 2022 | 443.65 Mn |
| Dec 31, 2021 | 442.10 Mn |
| Sep 30, 2021 | -388.36 Mn |
| Jun 30, 2021 | 439.09 Mn |